These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 23054640)

  • 41. Multi-omics signature of brain amyloid deposition in asymptomatic individuals at-risk for Alzheimer's disease: The INSIGHT-preAD study.
    Xicota L; Ichou F; Lejeune FX; Colsch B; Tenenhaus A; Leroy I; Fontaine G; Lhomme M; Bertin H; Habert MO; Epelbaum S; Dubois B; Mochel F; Potier MC;
    EBioMedicine; 2019 Sep; 47():518-528. PubMed ID: 31492558
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Pathogenesis, therapeutic strategies and biomarker development based on "omics" analysis related to microglia in Alzheimer's disease.
    Gao C; Shen X; Tan Y; Chen S
    J Neuroinflammation; 2022 Sep; 19(1):215. PubMed ID: 36058959
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Mass spectrometry-based urinary metabolomics for exploring the treatment effects of Radix ginseng-Schisandra chinensis herb pair on Alzheimer's disease in rats.
    Wang A; Pi Z; Liu S; Zheng Z; Liu Z; Song F
    J Sep Sci; 2021 Aug; 44(16):3158-3166. PubMed ID: 34110709
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Utility of Animal Models to Understand Human Alzheimer's Disease, Using the Mastermind Research Approach to Avoid Unnecessary Further Sacrifices of Animals.
    Qin T; Prins S; Groeneveld GJ; Van Westen G; de Vries HE; Wong YC; Bischoff LJM; de Lange ECM
    Int J Mol Sci; 2020 Apr; 21(9):. PubMed ID: 32365768
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Application of metabolomics based on direct mass spectrometry analysis for the elucidation of altered metabolic pathways in serum from the APP/PS1 transgenic model of Alzheimer's disease.
    González-Domínguez R; García-Barrera T; Vitorica J; Gómez-Ariza JL
    J Pharm Biomed Anal; 2015 Mar; 107():378-85. PubMed ID: 25656489
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Insulin resistance in Alzheimer's disease: The genetics and metabolomics links.
    Amin AM; Mostafa H; Khojah HMJ
    Clin Chim Acta; 2023 Jan; 539():215-236. PubMed ID: 36566957
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A review on omics-based biomarkers discovery for Alzheimer's disease from the bioinformatics perspectives: Statistical approach vs machine learning approach.
    Tan MS; Cheah PL; Chin AV; Looi LM; Chang SW
    Comput Biol Med; 2021 Dec; 139():104947. PubMed ID: 34678481
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Integrative metabolomics-genomics approach reveals key metabolic pathways and regulators of Alzheimer's disease.
    Horgusluoglu E; Neff R; Song WM; Wang M; Wang Q; Arnold M; Krumsiek J; Galindo-Prieto B; Ming C; Nho K; Kastenmüller G; Han X; Baillie R; Zeng Q; Andrews S; Cheng H; Hao K; Goate A; Bennett DA; Saykin AJ; Kaddurah-Daouk R; Zhang B; ;
    Alzheimers Dement; 2022 Jun; 18(6):1260-1278. PubMed ID: 34757660
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The contributions of metabolomics in the discovery of new therapeutic targets in Alzheimer's disease.
    Altiné-Samey R; Antier D; Mavel S; Dufour-Rainfray D; Balageas AC; Beaufils E; Emond P; Foucault-Fruchard L; Chalon S
    Fundam Clin Pharmacol; 2021 Jun; 35(3):582-594. PubMed ID: 33484165
    [TBL] [Abstract][Full Text] [Related]  

  • 50. NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease.
    Jack CR; Bennett DA; Blennow K; Carrillo MC; Dunn B; Haeberlein SB; Holtzman DM; Jagust W; Jessen F; Karlawish J; Liu E; Molinuevo JL; Montine T; Phelps C; Rankin KP; Rowe CC; Scheltens P; Siemers E; Snyder HM; Sperling R;
    Alzheimers Dement; 2018 Apr; 14(4):535-562. PubMed ID: 29653606
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Dissection of prodromal Alzheimer's disease.
    Sheng C; Huang Y; Han Y
    Front Biosci (Landmark Ed); 2018 Jan; 23(7):1272-1291. PubMed ID: 28930599
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Drug Repositioning for Alzheimer's Disease Based on Systematic 'omics' Data Mining.
    Zhang M; Schmitt-Ulms G; Sato C; Xi Z; Zhang Y; Zhou Y; St George-Hyslop P; Rogaeva E
    PLoS One; 2016; 11(12):e0168812. PubMed ID: 28005991
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Biosensing: The best alternative for conventional methods in detection of Alzheimer's disease biomarkers.
    Mobed A; Hasanzadeh M
    Int J Biol Macromol; 2020 Oct; 161():59-71. PubMed ID: 32504710
    [TBL] [Abstract][Full Text] [Related]  

  • 54. High-throughput metabolomics and ingenuity pathway approach reveals the pharmacological effect and targets of Ginsenoside Rg1 in Alzheimer's disease mice.
    Li G; Zhang N; Geng F; Liu G; Liu B; Lei X; Li G; Chen X
    Sci Rep; 2019 May; 9(1):7040. PubMed ID: 31065079
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Metabolomic profiling of serum in the progression of Alzheimer's disease by capillary electrophoresis-mass spectrometry.
    González-Domínguez R; García A; García-Barrera T; Barbas C; Gómez-Ariza JL
    Electrophoresis; 2014 Dec; 35(23):3321-30. PubMed ID: 25136972
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Toward a predictive model of Alzheimer's disease progression using capillary electrophoresis-mass spectrometry metabolomics.
    Ibáñez C; Simó C; Martín-Álvarez PJ; Kivipelto M; Winblad B; Cedazo-Mínguez A; Cifuentes A
    Anal Chem; 2012 Oct; 84(20):8532-40. PubMed ID: 22967182
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Recent advances in lipidomics for disease research.
    Yang L; Li M; Shan Y; Shen S; Bai Y; Liu H
    J Sep Sci; 2016 Jan; 39(1):38-50. PubMed ID: 26394722
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Metabolomics markers in Neurology: current knowledge and future perspectives for therapeutic targeting.
    Bonomo R; Cavaletti G; Skene DJ
    Expert Rev Neurother; 2020 Jul; 20(7):725-738. PubMed ID: 32538242
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Blood biomarkers in Alzheimer's disease.
    Altuna-Azkargorta M; Mendioroz-Iriarte M
    Neurologia (Engl Ed); 2021; 36(9):704-710. PubMed ID: 34752348
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Identifying Hair Biomarker Candidates for Alzheimer's Disease Using Three High Resolution Mass Spectrometry-Based Untargeted Metabolomics Strategies.
    Chang CW; Hsu JY; Hsiao PZ; Chen YC; Liao PC
    J Am Soc Mass Spectrom; 2023 Apr; 34(4):550-561. PubMed ID: 36973238
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.